Trial Profile

A one year efficacy study of Tofacitinib in Rheumatoid-arthritis patients who did not respond to conventional synthetic DMARDs

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tofacitinib (Primary) ; Methotrexate; Nonsteroidal anti-inflammatories; Prednisone
Indications Rheumatoid arthritis
Focus Therapeutic Use
Sponsors Pfizer

Most Recent Events

21 Jun 2019 New trial record
15 Jun 2019 Results of Escalation or De-escalation of dosage of Tofacitinib in rheumatoid arthritis Patients were presented at the 20th Annual Congress of the European League Against Rheumatism.
15 Jun 2019 One year efficacy results presented at the 20th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com